Metagenomi Therapeutics, Inc. (MGX)
0.99
-0.03
(-2.94%)
USD |
NASDAQ |
Oct 13, 11:20
Metagenomi Therapeutics Net Income (Quarterly) : -27.48M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -27.48M |
| March 31, 2026 | -23.06M |
| December 31, 2025 | -22.53M |
| September 30, 2025 | -20.39M |
| June 30, 2025 | -19.91M |
| March 31, 2025 | -25.04M |
| December 31, 2024 | -23.40M |
| September 30, 2024 | -18.77M |
| Date | Value |
|---|---|
| June 30, 2024 | -10.74M |
| March 31, 2024 | -25.15M |
| December 31, 2023 | -19.29M |
| September 30, 2023 | -19.82M |
| June 30, 2023 | -13.01M |
| March 31, 2023 | -16.13M |
| December 31, 2022 | -14.63M |
| September 30, 2022 | -10.38M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | -0.257M |
| Total Expenses (Quarterly) | 27.22M |
| EPS Diluted (Quarterly) | -0.7298 |
| Enterprise Value | -44.41M |
| Earnings Yield | -251.3% |
| Normalized Earnings Yield | -251.33 |